読み込み中
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
通常取引
$2.605
+$0.005 · +0.19%
日中の時刻はETです。市場データは遅延する場合があります。
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
日中レンジ
現在 $2.605
52週レンジ
現在 $2.605
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
42
適正価値
センチメント
59
まちまち
リスク
54
やや高いリスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
日中レンジ
現在 $2.605
52週レンジ
現在 $2.605
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.1万 USD | 2万 USD | 42.6万 USD | −6.8万 USD | 441万 USD |
| 粗利益 | 4.1万 USD | 2万 USD | 42.6万 USD | −6.8万 USD | 441万 USD |
| 研究開発 | 6643.2万 USD | 8222.6万 USD | 6579.9万 USD | 7053.8万 USD | 7454.1万 USD |
| 販売・一般管理 | 2809.8万 USD | 2096.6万 USD | 1813.7万 USD | 1713.4万 USD | 1541.3万 USD |
| 営業費用 | 9453万 USD | 1.03億 USD | 9635.5万 USD | 8767.2万 USD | 1.01億 USD |
| 受取利息 | 754.1万 USD | 807.4万 USD | 735.1万 USD | 287万 USD | 20.3万 USD |
| 支払利息 | 163.6万 USD | 9000 USD | 3.5万 USD | 8000 USD | 5000 USD |
| 減価償却費と償却費 | 11.2万 USD | 23.8万 USD | 47.7万 USD | 49.3万 USD | 55.1万 USD |
| 営業利益 | −9448.9万 USD | −1.03億 USD | −9592.9万 USD | −8774万 USD | −9691.4万 USD |
| 純利益 | −8809.3万 USD | −9505.9万 USD | −8844.7万 USD | −8471.3万 USD | −9709万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1787.87万0.00%2.3兆 USD0.03%$381.28+0.45%
iShares Russell 2000 ETFIWM1314.72万0.02%776.97億 USD0.19%$278.35+0.28%
State Street SPDR S&P Biotech ETFXBI1216.77万0.12%101.08億 USD0.35%$152.04+1.84%
Vanguard Extended Market ETFVXF704.69万0.01%954億 USD0.05%$234.29+0.50%
iShares Russell 2000 Value ETFIWN460.92万0.03%137.55億 USD0.24%$210.75-0.09%
Fidelity Enhanced Small Cap ETFFESM389.39万0.06%64.1億 USD0.28%$45.355+0.23%
iShares Biotechnology ETFIBB378.66万0.04%104.14億 USD0.44%$203.18+1.35%
Vanguard Russell 2000 ETFVTWO355.33万0.02%180億 USD0.06%$112.42+0.28%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
